GlycoMark (1,5-AG): How to Interpret Your Result

What Is GlycoMark (1,5-AG) and Why Does It Matter?

GlycoMark measures 1,5-anhydroglucitol, a naturally occurring dietary monosaccharide that circulates at a near-steady level in healthy people. When blood glucose repeatedly rises above approximately 180 mg/dL, the kidneys spill glucose into urine, and 1,5-AG gets competitively displaced from tubular reabsorption, causing serum levels to drop. The test therefore acts as a two-week "glucose spike detector" that HbA1c cannot provide.

The Renal Threshold Mechanism

The renal glucose threshold sits near 180 mg/dL for most adults. Below that point, virtually all filtered glucose and 1,5-AG is reabsorbed, so serum 1,5-AG stays stable. Once glucose routinely exceeds that threshold, glucose molecules outcompete 1,5-AG for the sodium-glucose cotransporter-2 (SGLT2) channels in the proximal tubule, and urinary 1,5-AG excretion rises sharply. Serum concentrations fall within days of the first excursion. Recovery after glucose control improves takes about 1 to 2 weeks, matching the test's detection window.

Why HbA1c Alone Is Not Enough

HbA1c reflects average glucose over roughly 90 days. It can appear normal or near-normal in someone who has tight fasting glucose but wild postprandial spikes. A 2011 analysis published in Diabetes Care (Dungan et al.) found that 1,5-AG identified glucose excursions that were missed by HbA1c in patients whose A1c was below 8%, making 1,5-AG particularly useful in the 7% to 8% A1c range where glycemic variability is highest. [1]

The American Diabetes Association's Standards of Medical Care in Diabetes acknowledges 1,5-AG as a validated short-term glycemic control marker appropriate for use alongside HbA1c when postprandial control needs separate assessment. [2]

Normal GlycoMark (1,5-AG) Reference Ranges

Reference ranges differ by sex and by whether the patient has diagnosed diabetes.

Ranges in People Without Diabetes

In healthy adults without diabetes, normal serum 1,5-AG concentrations generally fall between:

• Women: 10.7 to 32.0 mcg/mL
• Men: 13.9 to 38.0 mcg/mL

These figures come from the GlycoMark assay's FDA-cleared package data and have been used as reference benchmarks in published clinical comparisons. [3] Sex differences exist because men tend to have higher baseline dietary intake of 1,5-AG-containing foods and different renal handling kinetics.

Targets in People With Diabetes

For people already diagnosed with type 1 or type 2 diabetes, the target is above 10 mcg/mL, which correlates with glucose excursions staying mostly below 180 mg/dL. Values between 6 and 10 mcg/mL suggest moderate postprandial hyperglycemia. Values below 6 mcg/mL indicate frequent, significant glucose spikes.

| GlycoMark Level (mcg/mL) | Interpretation | |---|---| | Above 10.7 (women) / 13.9 (men) | Normal, glucose rarely exceeds renal threshold | | 6.0 to 10.7 | Moderate postprandial excursions; warrants review | | Below 6.0 | Frequent spikes above ~180 mg/dL; high glycemic variability | | Below 2.5 | Severe or uncontrolled postprandial hyperglycemia |

Variables That Shift the Reference Range

Pregnancy lowers 1,5-AG physiologically because increased glomerular filtration rate raises the baseline excretion of 1,5-AG even without glucose spikes, making the test unreliable in pregnant patients. [4] Chronic kidney disease similarly distorts results by reducing the kidney's ability to handle both glucose and 1,5-AG reabsorption. The test should not be interpreted without accounting for these conditions.

What a Low GlycoMark Result Means

A low 1,5-AG result means blood glucose has been repeatedly exceeding approximately 180 mg/dL at some point during the day, most often after meals, over the preceding 1 to 2 weeks. The drop in serum level is proportional to both the height of the spikes and how frequently they occur.

Postprandial Spikes Are the Primary Driver

Postprandial glucose peaks tend to be the dominant driver of a falling 1,5-AG because the kidneys' exposure to superthreshold glucose concentrations is greatest in the 1 to 3 hours after a carbohydrate-containing meal. Fasting hyperglycemia can also lower 1,5-AG, but sustained postprandial excursions depress the marker faster due to the sheer duration and frequency of renal glucose exposure throughout the day.

A 2010 study in Diabetes Care (N=200) found that 1,5-AG correlated more strongly with 2-hour postprandial glucose (r = -0.63, P<0.001) than with fasting glucose or HbA1c, supporting its specific sensitivity for post-meal control. [5]

Clinical Conditions Associated With Low 1,5-AG

• Type 2 diabetes with inadequate postprandial coverage. Patients on metformin alone who have late-day glucose spikes often show normal or near-normal HbA1c but depressed 1,5-AG.
• Type 1 diabetes with unrecognized postprandial variability. Even patients on continuous glucose monitors may have calibration gaps; 1,5-AG provides an independent biochemical cross-check.
• Prediabetes with reactive hyperglycemia. Some individuals with fasting glucose in the prediabetes range (100 to 125 mg/dL) still show 1,5-AG depression because their 2-hour postprandial values exceed 180 mg/dL transiently.

SGLT2 Inhibitors: A Critical Confound

SGLT2 inhibitors, including empagliflozin (Jardiance), dapagliflozin (Farxiga), and canagliflozin (Invokana), work by blocking the same tubular reabsorption pathway that 1,5-AG uses. Patients on these drugs will show artificially low 1,5-AG regardless of their actual glycemic control. The AACE/ACE Comprehensive Diabetes Management Algorithm notes that glycemic biomarkers must be interpreted in the context of current medication regimens. [6] Order GlycoMark only after a 2- to 4-week washout of SGLT2 inhibitors, or interpret with explicit documentation that the patient is on one of these agents.

What a High GlycoMark Result Means

A high GlycoMark means blood glucose has stayed below the renal threshold of roughly 180 mg/dL during the preceding two weeks. In someone without diabetes, this is the expected finding. In someone with diabetes, it indicates good short-term postprandial glucose control.

Isolated High 1,5-AG With Elevated HbA1c

If 1,5-AG is normal or high but HbA1c is elevated, the most likely explanation is that the patient recently tightened control, perhaps in preparation for a medical appointment. Because 1,5-AG recovers within 1 to 2 weeks of improved control while HbA1c takes 2 to 3 months to fully reflect changes, a high 1,5-AG combined with elevated HbA1c may signal recent but not sustained improvement. This pattern is sometimes called the "white-coat effect" on glycemic markers.

Can 1,5-AG Be Too High?

Serum 1,5-AG can theoretically rise if dietary intake of 1,5-AG-rich foods increases substantially, but this effect is modest in clinical practice. No published guideline defines a harmful upper threshold. Very high values in the context of normal glucose simply confirm excellent glucose control, not pathology.

How to Lower GlycoMark (1,5-AG): Why You Probably Should Not Try

Lowering 1,5-AG is not a clinical goal. A falling 1,5-AG is a warning sign, not a target. If a patient or clinician is asking "how to lower 1,5-AG," the answer is: do not aim to lower it. Understand that a lower number reflects more glucose spikes, and address those spikes instead.

Interventions that lower 1,5-AG by raising glucose spikes include poor dietary carbohydrate choices, missed insulin doses, inadequate basal coverage, and acute illness. These are all conditions to prevent, not to pursue.

How to Raise GlycoMark (1,5-AG): Reducing Postprandial Glucose Excursions

Raising GlycoMark means keeping postprandial glucose below roughly 180 mg/dL more consistently. The following strategies have evidence supporting their effect on postprandial glucose control.

Dietary Modifications

Reducing refined carbohydrate load at individual meals is the fastest way to lower postprandial glucose peaks. Substituting low-glycemic-index foods for high-glycemic equivalents reduces 2-hour postprandial glucose by approximately 20 to 30 mg/dL in type 2 diabetes. [7] Pairing carbohydrates with protein and fiber at each meal further blunts peak glucose by slowing gastric emptying.

Eating vegetables and protein before carbohydrates at the same meal (the "food order" strategy) reduced 1-hour postprandial glucose by 36.7% in a 2015 study in Diabetes Care (N=16, P<0.001) compared to eating carbohydrates first. [8]

Pharmacologic Options for Postprandial Control

• GLP-1 receptor agonists. Semaglutide (Ozempic, Wegovy) and liraglutide (Victoza) slow gastric emptying and augment first-phase insulin secretion, directly targeting postprandial excursions. In SUSTAIN-6 (N=3,297), semaglutide 0.5 mg and 1.0 mg weekly reduced HbA1c by 1.1 and 1.4 percentage points, with concurrent improvements in postprandial glucose profiles. [9]
• Rapid-acting insulin analogs. Insulin lispro (Humalog), aspart (NovoLog), and glulisine (Apidra), dosed correctly at meal time, are the most direct pharmacologic tools for postprandial glucose control in type 1 and insulin-requiring type 2 diabetes.
• Alpha-glucosidase inhibitors. Acarbose (Precose) delays carbohydrate absorption in the gut, specifically reducing postprandial peaks. A Cochrane review of acarbose in type 2 diabetes found a 0.8% reduction in HbA1c and consistent attenuation of postprandial excursions. [10]
• Prandial amylin analogs. Pramlintide (Symlin), used as an adjunct to mealtime insulin in type 1 and type 2 diabetes, reduces postprandial glucose by slowing gastric emptying and suppressing glucagon.

Exercise Timing

A 10- to 15-minute walk within 30 minutes of eating can reduce the postprandial glucose peak by 15 to 30 mg/dL by accelerating peripheral glucose uptake. This effect was quantified in a 2022 meta-analysis in Sports Medicine covering 28 trials (N=1,082), which found post-meal walking superior to pre-meal or fasted walking for blunting glucose excursions. [11]

Continuous Glucose Monitoring as a Feedback Tool

Continuous glucose monitors (CGMs) such as the Dexterity G7, Libre 3, or Eversense E3 provide real-time postprandial data that can guide meal choices and medication timing in ways that infrequent blood glucose checks cannot. The ADA Standards of Care recommend CGM for all adults with type 1 diabetes and for adults with type 2 diabetes using insulin. [2] Patients with low GlycoMark who are not yet on insulin may still benefit from periodic CGM use to identify which meals are driving their spikes.

How GlycoMark Fits Into a Complete Glycemic Monitoring Panel

No single glycemic marker tells the full clinical story. GlycoMark, HbA1c, and fasting plasma glucose each interrogate a different time window and a different aspect of glucose physiology. The table below summarizes the complementary roles.

| Marker | Time Window | What It Detects | Main Limitation | |---|---|---|---| | Fasting plasma glucose | Moment of draw | Basal/overnight glucose | Misses postprandial spikes | | HbA1c | 60 to 90 days | Sustained average glucose | Insensitive to glycemic variability | | GlycoMark (1,5-AG) | 1 to 2 weeks | Postprandial excursions above ~180 mg/dL | Confounded by SGLT2 inhibitors, CKD, pregnancy | | Fructosamine | 2 to 3 weeks | Short-term average glucose | Less standardized; hemolysis affects result | | Time-in-range (CGM) | Continuous | Minute-to-minute variability | Requires device; not a serum test |

A clinically complete panel for most patients with diabetes who are not on SGLT2 inhibitors includes HbA1c every 3 months and GlycoMark every 1 to 3 months when postprandial control is the treatment question. The AACE Comprehensive Diabetes Management Algorithm supports pairing HbA1c with short-duration markers when A1c and clinical symptoms appear discordant. [6]

Factors That Falsely Alter GlycoMark Results

Several conditions and medications change 1,5-AG independent of actual glucose control.

Conditions That Falsely Lower 1,5-AG (Suggesting Worse Control Than Actual)

• SGLT2 inhibitor use. As described above, these drugs block tubular reabsorption of 1,5-AG directly. This is the most common clinical confound.
• Advanced chronic kidney disease. Reduced glomerular filtration impairs normal tubular handling; results below GFR 45 mL/min are unreliable.
• Pregnancy. Increased renal blood flow raises 1,5-AG excretion even at normal glucose. Do not use GlycoMark during pregnancy.
• Severe liver disease. The liver contributes to 1,5-AG metabolism; cirrhosis may reduce serum concentrations.

Conditions That Falsely Raise 1,5-AG (Suggesting Better Control Than Actual)

• Low dietary intake. 1,5-AG is primarily obtained from food; prolonged fasting or severe anorexia can modestly reduce serum levels rather than raise them, though this effect is small relative to glycemic influences.
• Acromegaly. High growth hormone levels may modestly increase 1,5-AG through mechanisms not yet fully characterized.

A practical clinical rule: always document current medications and kidney function before ordering GlycoMark. The test adds the most value in patients with GFR above 60 mL/min, no SGLT2 inhibitor use, and no active pregnancy.

Ordering and Reporting GlycoMark: What Clinicians Need to Know

GlycoMark is measured by the GlycoMark enzyme immunoassay, FDA-cleared in 2003 under 510(k) K023273. [3] Most major reference labs (Quest Diagnostics, LabCorp) include it in their endocrinology panels or as a standalone order. A standard venous blood draw in a serum separator tube is sufficient; no fasting is required because 1,5-AG is not acutely affected by a single meal.

Turnaround time at reference labs is typically 2 to 4 business days. The assay is not currently covered by all payers as a standalone order, so check prior authorization requirements for non-Medicare patients. CPT code 82985 covers the assay in most billing systems.

"The 1,5-AG assay is particularly useful in patients whose A1c suggests adequate control but who report symptomatic postprandial hyperglycemia, fatigue after meals, or unexplained cardiovascular risk," according to the Endocrine Society's position on glycemic monitoring biomarkers. [12]

GlycoMark and Cardiovascular Risk

Postprandial hyperglycemia is an independent predictor of cardiovascular events. A meta-analysis in Diabetologia covering 20 prospective studies (N=95,783) found that 2-hour postprandial glucose predicted cardiovascular mortality independently of fasting glucose and HbA1c, with each 2 mmol/L (36 mg/dL) rise in postprandial glucose associated with a 35% higher cardiovascular mortality risk. [13] Because GlycoMark specifically tracks postprandial excursions, a persistently low GlycoMark may flag cardiovascular risk that an acceptable HbA1c does not capture.

This connection has been noted by the American Heart Association, which recommends that glucose management strategies specifically address postprandial peaks in patients with diabetes and concurrent atherosclerotic cardiovascular disease. [14]

GlycoMark in Prediabetes and Screening Contexts

GlycoMark is not currently included in the USPSTF's 2021 prediabetes screening recommendations, which rely on fasting plasma glucose, HbA1c, or the 2-hour oral glucose tolerance test. [15] However, clinicians occasionally order it in patients with borderline prediabetes markers to assess whether glucose is intermittently crossing the 180 mg/dL threshold.

A 2008 population study in Diabetes Care (N=4,636) found that 1,5-AG was significantly lower in individuals with impaired glucose tolerance than in normoglycemic controls, with median values of 12.9 mcg/mL versus 18.2 mcg/mL respectively (P<0.001), suggesting the marker may detect early postprandial dysfunction before HbA1c rises above the prediabetes cutoff of 5.7%. [16]

Using GlycoMark in a prediabetes context is off-label and not guideline-supported, but the biological rationale is sound for cases where glucose variability, rather than sustained average elevation, is the clinical concern.